KCM
JAZZ icon

Kingdon Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kingdon Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-36,000
Closed -$4.56M – 192
2013
Q4 		$4.56M Buy
+36,000
New +$3.73M 0.21% 128
2013
Q3 		– Sell
-49,439
Closed -$3.4M – 204
2013
Q2 		$3.4M Buy
+49,439
New +$3.02M 0.2% 127

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Kingdon Capital Management's JAZZ Position: Q1 2014 in Review

Kingdon Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2014, closing a stake of 36,000 shares — an estimated $4.56M sold.

Kingdon Capital Management first reported a position in JAZZ in Q2 2013 and held it in 2 quarters. The position peaked at $4.56M in Q4 2013. 318 funds tracked by Wall St. Rank hold JAZZ as of Q1 2014.

  • Kingdon Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Kingdon Capital Management sold 36,000 Jazz Pharmaceuticals shares in Q1 2014, an estimated $4.56M.
  • Kingdon Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Kingdon Capital Management's Jazz Pharmaceuticals position peaked at $4.56M in Q4 2013.
  • 318 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2014.

Based on Kingdon Capital Management's 13F filing for Q1 2014, filed 15 May 2014.